Key clinical point: Tumor mutational burden (TMB) status is associated with the clinical outcomes of the first-line pembrolizumab-based therapy in patients with advanced gastric cancer.

Major finding: TMB was significantly associated with the objective response rate, progression-free survival, and overall survival in the pembrolizumab monotherapy and pembrolizumab-chemotherapy treatment groups (1-sided P < .05) but not in the chemotherapy group (2-sided P > .05).

Study details: This prespecified exploratory analysis included 306 patients with advanced gastric cancer and evaluable TMB data who received pembrolizumab alone, pembrolizumab+chemotherapy, or chemotherapy alone in the phase 3 KEYNOTE-062 trial (n = 763).

Disclosures: This study was sponsored by Merck Sharp & Dohme (MSD) LLC, a subsidiary of Merck & Co., Inc., NJ Some authors reported receiving grants or personal fees from various sources, including MSD and Merck. Two authors declared being employees of MSD or Merck.

Source: Lee KW et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498 (Aug 15). Doi: 10.1158/1078-0432.CCR-22-0121

Key clinical point: Tumor mutational burden (TMB) status is associated with the clinical outcomes of the first-line pembrolizumab-based therapy in patients with advanced gastric cancer.

Major finding: TMB was significantly associated with the objective response rate, progression-free survival, and overall survival in the pembrolizumab monotherapy and pembrolizumab-chemotherapy treatment groups (1-sided P < .05) but not in the chemotherapy group (2-sided P > .05).

Study details: This prespecified exploratory analysis included 306 patients with advanced gastric cancer and evaluable TMB data who received pembrolizumab alone, pembrolizumab+chemotherapy, or chemotherapy alone in the phase 3 KEYNOTE-062 trial (n = 763).

Disclosures: This study was sponsored by Merck Sharp & Dohme (MSD) LLC, a subsidiary of Merck & Co., Inc., NJ Some authors reported receiving grants or personal fees from various sources, including MSD and Merck. Two authors declared being employees of MSD or Merck.

Source: Lee KW et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498 (Aug 15). Doi: 10.1158/1078-0432.CCR-22-0121

Key clinical point: Tumor mutational burden (TMB) status is associated with the clinical outcomes of the first-line pembrolizumab-based therapy in patients with advanced gastric cancer.

Major finding: TMB was significantly associated with the objective response rate, progression-free survival, and overall survival in the pembrolizumab monotherapy and pembrolizumab-chemotherapy treatment groups (1-sided P < .05) but not in the chemotherapy group (2-sided P > .05).

Study details: This prespecified exploratory analysis included 306 patients with advanced gastric cancer and evaluable TMB data who received pembrolizumab alone, pembrolizumab+chemotherapy, or chemotherapy alone in the phase 3 KEYNOTE-062 trial (n = 763).

Disclosures: This study was sponsored by Merck Sharp & Dohme (MSD) LLC, a subsidiary of Merck & Co., Inc., NJ Some authors reported receiving grants or personal fees from various sources, including MSD and Merck. Two authors declared being employees of MSD or Merck.

Source: Lee KW et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498 (Aug 15). Doi: 10.1158/1078-0432.CCR-22-0121

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.

Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.

Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.

Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.

Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z

Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.

Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.

Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.

Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.

Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z

Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.

Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.

Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.

Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.

Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z

Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).

Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P  =  .0412) and in those without vs with signs of disease progression (P  =  .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P  =  .0257) and PFS (P  =  .0141).

Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.

Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.

Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815

Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).

Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P  =  .0412) and in those without vs with signs of disease progression (P  =  .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P  =  .0257) and PFS (P  =  .0141).

Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.

Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.

Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815

Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).

Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P  =  .0412) and in those without vs with signs of disease progression (P  =  .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P  =  .0257) and PFS (P  =  .0141).

Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.

Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.

Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815

Key clinical point: The coadministration of histamine H₂ receptor antagonists (H₂RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).

Major finding: At 5 years, the relapse-free survival (RFS) in the H₂RA and non-H₂RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H₂RA and non-H₂RA groups of patients receiving capecitabine monotherapy or CapeOX (P  =  .772).

Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H₂RA were coadministered to 30 patients.

Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.

Source: Yamazaki T et al. Association between the co-administration of histamine H₂ receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385

Key clinical point: The coadministration of histamine H₂ receptor antagonists (H₂RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).

Major finding: At 5 years, the relapse-free survival (RFS) in the H₂RA and non-H₂RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H₂RA and non-H₂RA groups of patients receiving capecitabine monotherapy or CapeOX (P  =  .772).

Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H₂RA were coadministered to 30 patients.

Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.

Source: Yamazaki T et al. Association between the co-administration of histamine H₂ receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385

Key clinical point: The coadministration of histamine H₂ receptor antagonists (H₂RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).

Major finding: At 5 years, the relapse-free survival (RFS) in the H₂RA and non-H₂RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H₂RA and non-H₂RA groups of patients receiving capecitabine monotherapy or CapeOX (P  =  .772).

Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H₂RA were coadministered to 30 patients.

Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.

Source: Yamazaki T et al. Association between the co-administration of histamine H₂ receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385

Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.

Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.

Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.

Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.

Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9

Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.

Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.

Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.

Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.

Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9

Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.

Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.

Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.

Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.

Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9

Key clinical point: The response to standard treatments is disappointing in patients with KRASG12C-mutant metastatic colorectal cancer (mCRC), highlighting an urgent need for target therapies with selective KRASG12C inhibitors.

Major finding: The overall response rate was 38.7%, and the median progression-free survival and overall survival were 9 months (95% CI 7.5-10.5) and 21 months (95% CI 17.4-24.6), respectively. Only 62% and 36% of the patients who progressed received a second- and third-line treatment, respectively, with limited clinical benefits.

Study details: Findings are from a retrospective analysis of 111 patients with unresectable mCRC harboring KRASG12C mutation who received first-line doublet or triplet chemotherapy.

Disclosures: The study did not declare any source of funding. Some authors declared serving as consultants, advisors, or speakers for or receiving personal fees, travel and accommodation expenses, or research grants from various sources.

Source: Ciardiello D et al. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: Findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open. 2022;7(5):100567 (Aug 19). Doi: 10.1016/j.esmoop.2022.100567

Key clinical point: The response to standard treatments is disappointing in patients with KRASG12C-mutant metastatic colorectal cancer (mCRC), highlighting an urgent need for target therapies with selective KRASG12C inhibitors.

Major finding: The overall response rate was 38.7%, and the median progression-free survival and overall survival were 9 months (95% CI 7.5-10.5) and 21 months (95% CI 17.4-24.6), respectively. Only 62% and 36% of the patients who progressed received a second- and third-line treatment, respectively, with limited clinical benefits.

Study details: Findings are from a retrospective analysis of 111 patients with unresectable mCRC harboring KRASG12C mutation who received first-line doublet or triplet chemotherapy.

Disclosures: The study did not declare any source of funding. Some authors declared serving as consultants, advisors, or speakers for or receiving personal fees, travel and accommodation expenses, or research grants from various sources.

Source: Ciardiello D et al. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: Findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open. 2022;7(5):100567 (Aug 19). Doi: 10.1016/j.esmoop.2022.100567

Key clinical point: The response to standard treatments is disappointing in patients with KRASG12C-mutant metastatic colorectal cancer (mCRC), highlighting an urgent need for target therapies with selective KRASG12C inhibitors.

Major finding: The overall response rate was 38.7%, and the median progression-free survival and overall survival were 9 months (95% CI 7.5-10.5) and 21 months (95% CI 17.4-24.6), respectively. Only 62% and 36% of the patients who progressed received a second- and third-line treatment, respectively, with limited clinical benefits.

Study details: Findings are from a retrospective analysis of 111 patients with unresectable mCRC harboring KRASG12C mutation who received first-line doublet or triplet chemotherapy.

Disclosures: The study did not declare any source of funding. Some authors declared serving as consultants, advisors, or speakers for or receiving personal fees, travel and accommodation expenses, or research grants from various sources.

Source: Ciardiello D et al. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: Findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open. 2022;7(5):100567 (Aug 19). Doi: 10.1016/j.esmoop.2022.100567

Key clinical point: A significant association was observed between high intake of red and processed meat and the presence of advanced colorectal lesions at colonoscopy in fecal occult blood test (FIT)-positive participants.

Major finding: Each 100 g/day increase in the intake of red and processed meat increased the risk for advanced colorectal lesion by 32% (odds ratio [OR] 1.32; 95% CI 1.09-1.60). The risk was prominent among patients with high vs low (≥100 vs <50 g/day) absolute intake of processed meat (OR 1.19; 95% CI 1.09-1.31).

Study details: This study evaluated associations between red and processed meat intake and screen-detected colorectal lesions in 1162 FIT-positive participants from the Norwegian CRCbiome study.

Disclosures: This study was supported by the Norwegian Cancer Society, the Research Council of Norway, and the South Eastern Norway Regional Health Authority. No competing interests were declared.

Source: Kværner AS et al. Associations of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr. 2022 (Sep 7). Doi: 10.1017/S0007114522002860

Key clinical point: A significant association was observed between high intake of red and processed meat and the presence of advanced colorectal lesions at colonoscopy in fecal occult blood test (FIT)-positive participants.

Major finding: Each 100 g/day increase in the intake of red and processed meat increased the risk for advanced colorectal lesion by 32% (odds ratio [OR] 1.32; 95% CI 1.09-1.60). The risk was prominent among patients with high vs low (≥100 vs <50 g/day) absolute intake of processed meat (OR 1.19; 95% CI 1.09-1.31).

Study details: This study evaluated associations between red and processed meat intake and screen-detected colorectal lesions in 1162 FIT-positive participants from the Norwegian CRCbiome study.

Disclosures: This study was supported by the Norwegian Cancer Society, the Research Council of Norway, and the South Eastern Norway Regional Health Authority. No competing interests were declared.

Source: Kværner AS et al. Associations of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr. 2022 (Sep 7). Doi: 10.1017/S0007114522002860

Key clinical point: A significant association was observed between high intake of red and processed meat and the presence of advanced colorectal lesions at colonoscopy in fecal occult blood test (FIT)-positive participants.

Major finding: Each 100 g/day increase in the intake of red and processed meat increased the risk for advanced colorectal lesion by 32% (odds ratio [OR] 1.32; 95% CI 1.09-1.60). The risk was prominent among patients with high vs low (≥100 vs <50 g/day) absolute intake of processed meat (OR 1.19; 95% CI 1.09-1.31).

Study details: This study evaluated associations between red and processed meat intake and screen-detected colorectal lesions in 1162 FIT-positive participants from the Norwegian CRCbiome study.

Disclosures: This study was supported by the Norwegian Cancer Society, the Research Council of Norway, and the South Eastern Norway Regional Health Authority. No competing interests were declared.

Source: Kværner AS et al. Associations of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr. 2022 (Sep 7). Doi: 10.1017/S0007114522002860

Key clinical point: Fecal immunochemical testing (FIT) at a threshold of ≥10 μg of hemoglobin per gram of feces safely triaged primary care patients with low-risk symptoms, with negative results effectively ruling out colorectal cancer (CRC).

Major finding: The sensitivity, specificity, positive predictive value, and negative predictive value of FIT for CRC detection at a fecal hemoglobin cutoff of ≥10 μg/g were 91.1% (95% CI 77.9%-97.1%), 80.7% (95% CI 79.3%-82.0%), 5.8% (95% CI 4.2%-7.8%), and 99.9% (95% CI 99.60%-99.95%), respectively, and the area under the receiver operating characteristic curve was 0.93 (95% CI 0.91-0.96).

Study details: This study included 3506 low-risk symptomatic adult patients managed in primary care who were referred for FIT.

Disclosures: This study was supported by the South Yorkshire, Bassetlaw & North Derbyshire Cancer Alliance, UK. The authors declared no conflicts of interest.

Source: Ball AJ et al. Fecal immunochemical testing in patients with low-risk symptoms of colorectal cancer: A diagnostic accuracy study. J Natl Compr Canc Netw. 2022;20(9):989-996.e1 (Sep). Doi: 10.6004/jnccn.2022.7037

Key clinical point: Fecal immunochemical testing (FIT) at a threshold of ≥10 μg of hemoglobin per gram of feces safely triaged primary care patients with low-risk symptoms, with negative results effectively ruling out colorectal cancer (CRC).

Major finding: The sensitivity, specificity, positive predictive value, and negative predictive value of FIT for CRC detection at a fecal hemoglobin cutoff of ≥10 μg/g were 91.1% (95% CI 77.9%-97.1%), 80.7% (95% CI 79.3%-82.0%), 5.8% (95% CI 4.2%-7.8%), and 99.9% (95% CI 99.60%-99.95%), respectively, and the area under the receiver operating characteristic curve was 0.93 (95% CI 0.91-0.96).

Study details: This study included 3506 low-risk symptomatic adult patients managed in primary care who were referred for FIT.

Disclosures: This study was supported by the South Yorkshire, Bassetlaw & North Derbyshire Cancer Alliance, UK. The authors declared no conflicts of interest.

Source: Ball AJ et al. Fecal immunochemical testing in patients with low-risk symptoms of colorectal cancer: A diagnostic accuracy study. J Natl Compr Canc Netw. 2022;20(9):989-996.e1 (Sep). Doi: 10.6004/jnccn.2022.7037

Key clinical point: Fecal immunochemical testing (FIT) at a threshold of ≥10 μg of hemoglobin per gram of feces safely triaged primary care patients with low-risk symptoms, with negative results effectively ruling out colorectal cancer (CRC).

Major finding: The sensitivity, specificity, positive predictive value, and negative predictive value of FIT for CRC detection at a fecal hemoglobin cutoff of ≥10 μg/g were 91.1% (95% CI 77.9%-97.1%), 80.7% (95% CI 79.3%-82.0%), 5.8% (95% CI 4.2%-7.8%), and 99.9% (95% CI 99.60%-99.95%), respectively, and the area under the receiver operating characteristic curve was 0.93 (95% CI 0.91-0.96).

Study details: This study included 3506 low-risk symptomatic adult patients managed in primary care who were referred for FIT.

Disclosures: This study was supported by the South Yorkshire, Bassetlaw & North Derbyshire Cancer Alliance, UK. The authors declared no conflicts of interest.

Source: Ball AJ et al. Fecal immunochemical testing in patients with low-risk symptoms of colorectal cancer: A diagnostic accuracy study. J Natl Compr Canc Netw. 2022;20(9):989-996.e1 (Sep). Doi: 10.6004/jnccn.2022.7037

Key clinical point: Acquired genomic alterations (Acq-Gas) associated with epidermal growth factor receptor (EGFR)-resistance in later lines were rare with first-line anti-EGFR-antibody combined with highly active chemotherapy and comparable with non-anti-EGFR regimen.

Major finding: On progression, ≥1 Acq-GA of interest developed in 6.6% of patients on anti-EGFR-chemotherapy compared with 10.1% of patients on anti-vascular endothelial growth factor (VEGF)-chemotherapy (odds ratio [OR] 0.62; 95% CI 0.20-2.11) and 62.0% of patients on anti-EGFR-antibody therapy in later lines (OR 0.09; 95% CI 0.03-0.23).

Study details: This was a post hoc analysis of the CALGB/SWOG-80405 trial including patients with mCRC who progressed on first-line cetuximab (anti-EGFR)-chemotherapy or bevacizumab (anti-VEGF)-chemotherapy and had pretreatment and post-progression plasma samples available for circulating tumor DNA testing.

Disclosures: This study was supported by the National Cancer Institute of the US National Institutes of Health. Some authors declared receiving honoraria or research funding from, having consulting or advisory roles or stock or other ownership interests in, or serving on speakers’ bureau for various sources.

Source: Raghav K et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol. 2022 (Sep 6). Doi: 10.1200/JCO.22.00365

Key clinical point: Acquired genomic alterations (Acq-Gas) associated with epidermal growth factor receptor (EGFR)-resistance in later lines were rare with first-line anti-EGFR-antibody combined with highly active chemotherapy and comparable with non-anti-EGFR regimen.

Major finding: On progression, ≥1 Acq-GA of interest developed in 6.6% of patients on anti-EGFR-chemotherapy compared with 10.1% of patients on anti-vascular endothelial growth factor (VEGF)-chemotherapy (odds ratio [OR] 0.62; 95% CI 0.20-2.11) and 62.0% of patients on anti-EGFR-antibody therapy in later lines (OR 0.09; 95% CI 0.03-0.23).

Study details: This was a post hoc analysis of the CALGB/SWOG-80405 trial including patients with mCRC who progressed on first-line cetuximab (anti-EGFR)-chemotherapy or bevacizumab (anti-VEGF)-chemotherapy and had pretreatment and post-progression plasma samples available for circulating tumor DNA testing.

Disclosures: This study was supported by the National Cancer Institute of the US National Institutes of Health. Some authors declared receiving honoraria or research funding from, having consulting or advisory roles or stock or other ownership interests in, or serving on speakers’ bureau for various sources.

Source: Raghav K et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol. 2022 (Sep 6). Doi: 10.1200/JCO.22.00365

Key clinical point: Acquired genomic alterations (Acq-Gas) associated with epidermal growth factor receptor (EGFR)-resistance in later lines were rare with first-line anti-EGFR-antibody combined with highly active chemotherapy and comparable with non-anti-EGFR regimen.

Major finding: On progression, ≥1 Acq-GA of interest developed in 6.6% of patients on anti-EGFR-chemotherapy compared with 10.1% of patients on anti-vascular endothelial growth factor (VEGF)-chemotherapy (odds ratio [OR] 0.62; 95% CI 0.20-2.11) and 62.0% of patients on anti-EGFR-antibody therapy in later lines (OR 0.09; 95% CI 0.03-0.23).

Study details: This was a post hoc analysis of the CALGB/SWOG-80405 trial including patients with mCRC who progressed on first-line cetuximab (anti-EGFR)-chemotherapy or bevacizumab (anti-VEGF)-chemotherapy and had pretreatment and post-progression plasma samples available for circulating tumor DNA testing.

Disclosures: This study was supported by the National Cancer Institute of the US National Institutes of Health. Some authors declared receiving honoraria or research funding from, having consulting or advisory roles or stock or other ownership interests in, or serving on speakers’ bureau for various sources.

Source: Raghav K et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol. 2022 (Sep 6). Doi: 10.1200/JCO.22.00365